Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.

van Westen E, Poelen MCM, van den Dobbelsteen GPJM, Oloo EO, Ochs MM, Rots NY, van Els CACM.

PLoS One. 2018 Mar 6;13(3):e0193650. doi: 10.1371/journal.pone.0193650. eCollection 2018.

2.

Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli Vaccine.

Abbanat D, Davies TA, Amsler K, He W, Fae K, Janssen S, Poolman JT, van den Dobbelsteen GPJM.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00123-17. doi: 10.1128/CVI.00123-17. Print 2017 Dec.

3.

A Meningococcal Outer Membrane Vesicle Vaccine Incorporating Genetically Attenuated Endotoxin Dissociates Inflammation from Immunogenicity.

Dowling DJ, Sanders H, Cheng WK, Joshi S, Brightman S, Bergelson I, Pietrasanta C, van Haren SD, van Amsterdam S, Fernandez J, van den Dobbelsteen GP, Levy O.

Front Immunol. 2016 Dec 8;7:562. doi: 10.3389/fimmu.2016.00562. eCollection 2016.

4.

Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models.

van den Dobbelsteen GPJM, Faé KC, Serroyen J, van den Nieuwenhof IM, Braun M, Haeuptle MA, Sirena D, Schneider J, Alaimo C, Lipowsky G, Gambillara-Fonck V, Wacker M, Poolman JT.

Vaccine. 2016 Jul 29;34(35):4152-4160. doi: 10.1016/j.vaccine.2016.06.067. Epub 2016 Jul 6.

PMID:
27395567
5.

Importance of (antibody-dependent) complement-mediated serum killing in protection against Bordetella pertussis.

Geurtsen J, Fae KC, van den Dobbelsteen GP.

Expert Rev Vaccines. 2014 Oct;13(10):1229-40. doi: 10.1586/14760584.2014.944901. Epub 2014 Aug 1. Review.

PMID:
25081731
6.

The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines.

Queenan AM, Fernandez J, Shang W, Wiertsema S, van den Dobbelsteen GP, Poolman J.

Expert Rev Vaccines. 2014 Oct;13(10):1265-70. doi: 10.1586/14760584.2014.938642. Epub 2014 Jul 17.

PMID:
25029905
7.

The history of pneumococcal conjugate vaccine development: dose selection.

Poolman JT, Peeters CC, van den Dobbelsteen GP.

Expert Rev Vaccines. 2013 Dec;12(12):1379-94. doi: 10.1586/14760584.2013.852475. Review.

PMID:
24195479
8.

Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose.

van Westen E, Rodenburg GD, van Gils EJ, Tcherniaeva I, Berbers GA, Cowell L, Goldblatt D, Rots NY, van den Dobbelsteen GP, Sanders EA.

Vaccine. 2013 Dec 2;31(49):5834-42. doi: 10.1016/j.vaccine.2013.09.073. Epub 2013 Oct 10.

9.

Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.

van de Waterbeemd B, Zomer G, Kaaijk P, Ruiterkamp N, Wijffels RH, van den Dobbelsteen GP, van der Pol LA.

PLoS One. 2013 May 31;8(5):e65157. doi: 10.1371/journal.pone.0065157. Print 2013.

10.

Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.

Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GP, Postma MJ.

Hum Vaccin Immunother. 2013 May;9(5):1129-38. doi: 10.4161/hv.23888. Epub 2013 Feb 13.

11.

Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease.

Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EP, Levels LM, van Dijken HH, van den Dobbelsteen GP.

Vaccine. 2013 Feb 4;31(7):1065-71. doi: 10.1016/j.vaccine.2012.12.031. Epub 2012 Dec 27.

PMID:
23273968
12.

Preclinical evaluation of MenB vaccines: prerequisites for clinical development.

Sanders H, Kaaijk P, van den Dobbelsteen GP.

Expert Rev Vaccines. 2013 Jan;12(1):31-42. doi: 10.1586/erv.12.137. Review.

PMID:
23256737
13.

Resurgence of pertussis calls for re-evaluation of pertussis animal models.

van der Ark AA, Hozbor DF, Boog CJ, Metz B, van den Dobbelsteen GP, van Els CA.

Expert Rev Vaccines. 2012 Sep;11(9):1121-37. doi: 10.1586/erv.12.83. Review.

PMID:
23151168
14.

Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.

Rodenburg GD, Sanders EA, van Gils EJ, Veenhoven RH, Zborowski T, van den Dobbelsteen GP, Bloem AC, Berbers GA, Bogaert D.

PLoS One. 2012;7(10):e46916. doi: 10.1371/journal.pone.0046916. Epub 2012 Oct 16.

15.

Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis.

Spijkerman J, Prevaes SM, van Gils EJ, Veenhoven RH, Bruin JP, Bogaert D, Wijmenga-Monsuur AJ, van den Dobbelsteen GP, Sanders EA.

PLoS One. 2012;7(6):e39730. doi: 10.1371/journal.pone.0039730. Epub 2012 Jun 25. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/2b5d32c3-808f-4759-8207-0a953e4ad01d.

16.

Nonclinical vaccine safety evaluation: advantages of continuous temperature monitoring using abdominally implanted data loggers.

Kaaijk P, van der Ark AA, van Amerongen G, van den Dobbelsteen GP.

J Appl Toxicol. 2013 Jun;33(6):521-6. doi: 10.1002/jat.2720. Epub 2012 Mar 8.

PMID:
22407801
17.

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.

Kaaijk P, van der Ende A, Berbers G, van den Dobbelsteen GP, Rots NY.

BMC Infect Dis. 2012 Feb 8;12:35. doi: 10.1186/1471-2334-12-35.

18.

Lower immunoglobulin G antibody responses to pneumococcal conjugate vaccination at the age of 2 years after previous nasopharyngeal carriage of Streptococcus pneumoniae.

Rodenburg GD, van Gils EJ, Veenhoven RH, Bogaert D, van den Dobbelsteen GP, Berbers GA, Sanders EA.

J Pediatr. 2011 Dec;159(6):965-70.e1. doi: 10.1016/j.jpeds.2011.06.011. Epub 2011 Aug 2.

PMID:
21813135
19.

A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques.

Hoogerhout P, Kamphuis W, Brugghe HF, Sluijs JA, Timmermans HA, Westdijk J, Zomer G, Boog CJ, Hol EM, van den Dobbelsteen GP.

PLoS One. 2011 Apr 19;6(4):e19110. doi: 10.1371/journal.pone.0019110.

20.

Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands.

Spijkerman J, van Gils EJ, Veenhoven RH, Hak E, Yzerman EP, van der Ende A, Wijmenga-Monsuur AJ, van den Dobbelsteen GP, Sanders EA.

Emerg Infect Dis. 2011 Apr;17(4):584-91. doi: 10.3201/eid1704.101115.

21.

The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease.

Fransen F, Hamstra HJ, Boog CJ, van Putten JP, van den Dobbelsteen GP, van der Ley P.

Infect Immun. 2010 Jul;78(7):3177-86. doi: 10.1128/IAI.01311-09. Epub 2010 May 3.

22.

Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model.

Luijkx TA, van Gaans-van den Brink JA, van Dijken HH, van den Dobbelsteen GP, van Els CA.

Clin Vaccine Immunol. 2008 Oct;15(10):1598-605. doi: 10.1128/CVI.00192-08. Epub 2008 Sep 3.

23.

Bioneedles as vaccine carriers.

Hirschberg HJ, van de Wijdeven GG, Kelder AB, van den Dobbelsteen GP, Kersten GF.

Vaccine. 2008 May 2;26(19):2389-97. doi: 10.1016/j.vaccine.2008.02.067. Epub 2008 Mar 25.

PMID:
18406021
24.

On the design of national vaccination programmes.

van der Zeijst BA, Dijkman MI, Luytjes W, van Alphen AJ, van den Dobbelsteen GP.

Vaccine. 2007 Apr 20;25(16):3143-5. Epub 2007 Jan 29. Review.

PMID:
17293011
25.

Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs.

van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L.

Vaccine. 2007 Mar 22;25(13):2491-6. Epub 2006 Sep 20.

PMID:
17023098
26.

CC and CXC chemokine levels in children with meningococcal sepsis accurately predict mortality and disease severity.

Vermont CL, Hazelzet JA, de Kleijn ED, van den Dobbelsteen GP, de Groot R.

Crit Care. 2006 Feb;10(1):R33.

27.

Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease.

Vermont CL, van Dijken HH, de Groot R, van den Dobbelsteen GP.

Pediatr Res. 2005 Jul;58(1):149-52. Epub 2005 Mar 17.

PMID:
15774845
28.

PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children.

Vermont CL, Van Dijken HH, De Groot R, Van Alphen L, Van Den Dobbelsteen GP.

Vaccine. 2004 Aug 13;22(23-24):3008-13.

PMID:
15297049
29.

Meningococcal serogroup B infections: a search for a broadly protective vaccine.

Vermont CL, van den Dobbelsteen GP.

Expert Rev Vaccines. 2003 Oct;2(5):673-81. Review.

PMID:
14711328
30.

Recent developments in vaccines to prevent meningococcal serogroup B infections.

Vermont CL, van den Dobbelsteen GP, de Groot R.

Curr Opin Mol Ther. 2003 Feb;5(1):33-8. Review.

PMID:
12669468
31.

Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, Kuipers AJ, van Limpt CJ, Keijzers WC, van der Ende A, de Groot R, van Alphen L, van den Dobbelsteen GP.

Infect Immun. 2003 Apr;71(4):1650-5.

32.

Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP.

Infect Immun. 2002 Feb;70(2):584-90.

33.

Roles of interleukin-6 and macrophage inflammatory protein-2 in pneumolysin-induced lung inflammation in mice.

Rijneveld AW, van den Dobbelsteen GP, Florquin S, Standiford TJ, Speelman P, van Alphen L, van der Poll T.

J Infect Dis. 2002 Jan 1;185(1):123-6. Epub 2001 Nov 30.

PMID:
11756992
34.

Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides.

Breukels MA, Zandvoort A, van Den Dobbelsteen GP, van Den Muijsenberg A, Lodewijk ME, Beurret M, Klok PA, Timens W, Rijkers GT.

Infect Immun. 2001 Dec;69(12):7583-7.

35.

A new rat model of otitis media caused by Streptococcus pneumoniae: conditions and application in immunization protocols.

van der Ven LT, van den Dobbelsteen GP, Nagarajah B, van Dijken H, Dortant PM, Vos JG, Roholl PJ.

Infect Immun. 1999 Nov;67(11):6098-103.

36.

Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response.

Rodriguez ME, van den Dobbelsteen GP, Oomen LA, de Weers O, van Buren L, Beurret M, Poolman JT, Hoogerhout P.

Vaccine. 1998 Dec;16(20):1941-9.

PMID:
9796048
37.

Long-term gender-specific effects of manipulation during pregnancy on immune and endocrine responsiveness in rat offspring.

Bakker JM, van den Dobbelsteen GP, Kroes H, Kavelaars A, Heijnen CJ, Tilders FJ, van Rees EP.

J Neuroimmunol. 1998 Feb;82(1):56-63.

PMID:
9526846
38.

The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens.

Wijburg OL, van den Dobbelsteen GP, Vadolas J, Sanders A, Strugnell RA, van Rooijen N.

Eur J Immunol. 1998 Feb;28(2):479-87.

39.

Macrophages in host defense mechanisms.

van Rooijen N, Wijburg OL, van den Dobbelsteen GP, Sanders A.

Curr Top Microbiol Immunol. 1996;210:159-65. Review. No abstract available.

PMID:
8565554
40.

Mucosal immune responses to pneumococcal polysaccharides: implications for vaccination.

van den Dobbelsteen GP, van Rees EP.

Trends Microbiol. 1995 Apr;3(4):155-9. Review.

PMID:
7613758
41.

Characteristics of immune responses to native and protein conjugated pneumococcal polysaccharide type 14.

van den Dobbelsteen GP, Kroes H, van Rees EP.

Scand J Immunol. 1995 Mar;41(3):273-80.

PMID:
7871387
42.

Ontogeny of the mucosal immune response against different types of pneumococcal polysaccharide in rat.

van den Dobbelsteen GP, Brunekreef K, Kroes H, Sminia T, van Rees EP.

Adv Exp Med Biol. 1995;371A:415-9. No abstract available.

PMID:
8525956
43.

Mucosal and systemic immunization with pneumococcal polysaccharide type 3, 4 and 14 in the rat.

van den Dobbelsteen GP, Brunekreef K, Sminia T, van Rees EP.

Adv Exp Med Biol. 1995;371B:1605-10. No abstract available.

PMID:
7502866
44.

Enhanced triggering of mucosal immune responses by reducing splenic phagocytic functions.

van den Dobbelsteen GP, Brunekreef K, Kroes H, van Rooijen N, van Rees EP.

Eur J Immunol. 1993 Jul;23(7):1488-93.

PMID:
8325324
45.

The in vivo antibody response in rat gut-associated lymphoid tissue (GALT) after immunization with bacterial polysaccharide antigen.

Soesatyo M, Van den Dobbelsteen GP, Van Rees EP, Biewenga J, Sminia T.

Res Immunol. 1993 Feb;144(2):121-8.

PMID:
8516557
46.

Effect of mucosal and systemic immunization with pneumococcal polysaccharide type 3, 4 and 14 in the rat.

van den Dobbelsteen GP, Brunekreef K, Sminia T, van Rees EP.

Scand J Immunol. 1992 Nov;36(5):661-9.

PMID:
1439579
47.

Supplemental Content

Loading ...
Support Center